Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Numerous studies have established the correlation between antibodies to the core protein p24 of HIV-1 and the progression of the acquired immunodeficiency syndrome. In this study, we analyzed the immune response to two recombinant gag proteins, p24 and p17, in order to evaluate their diagnostic or prognostic significance. Immune response to the immunodominant domain of the transmembrane glycoprotein gp41 was used as a reference. Sera collected from individuals from France and Burundi (Central Africa) at various CDC stages of HIV-1 infection were tested using three sandwich enzyme-linked immunoassays developed with a synthetic peptide corresponding to the immunodominant domain of gp41, SP gp41, or recombinant p24 and p17 cloned and expressed in Escherichia coli. These assays allowed detection of titer antibodies to the three cited antigens. Antibodies to SP gp41 were detected in every HIV-1-positive patient from France and Burundi, generally at a high and stable level. Results obtained with p24 confirmed the value of antibodies to p24 as a prognostic marker only in European and North American populations, since the African population had very high levels of these antibodies even at an advanced stage of the disease. They also confirmed that initial antibody response to p24 is more predictive of outcome than antibody titer change over time. Although antibodies to p17 decline during progression to AIDS, they are frequently absent in French patients at early, asymptomatic stages and therefore could not be used as a prognostic marker. In contrast, antibodies to p17 are significantly less common in African patients with AIDS when compared with symptomless HIV-1-infected African individuals.(ABSTRACT TRUNCATED AT 250 WORDS)
Janvier
B
B
Unité de Virologie, URA CNRS 1334, CHRU Bretonneau, Tours, France.
Mallet
F
F
Cheynet
V
V
Dalbon
P
P
Vernet
G
G
Besnier
J M
JM
Choutet
P
P
Goudeau
A
A
Mandrand
B
B
Barin
F
F
D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology / Q000276:immunology; D002063:Burundi / Q000453:epidemiology; D005602:France / Q000453:epidemiology; D015683:Gene Products, gag / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000097:blood; D015488:HIV Antigens / Q000276:immunology*; D016655:HIV Core Protein p24 / Q000276:immunology*; D015700:HIV Envelope Protein gp41 / Q000276:immunology; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D015994:Incidence; D008137:Longitudinal Studies; D015995:Prevalence; D011379:Prognosis; D011994:Recombinant Proteins / Q000276:immunology; D014763:Viral Matrix Proteins / Q000276:immunology; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D016655:HIV Core Protein p24; D015700:HIV Envelope Protein gp41; D011994:Recombinant Proteins; D014763:Viral Matrix Proteins; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1